Use of angiotensin-converting enzyme inhibitors in patients with diabetic nephropathy

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 12, Issue 6, 2002, Pages 402-407

  How, H Y ^a   Sibai, B M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor antagonists; Diabetic nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; CAPTOTEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; FOSINOPRIL; LISINOPRIL; MOEXIPRIL; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; TRANDOLAPRILAT;

ACUTE KIDNEY FAILURE; ANGIONEUROTIC EDEMA; CONFERENCE PAPER; COUGHING; DIABETIC NEPHROPATHY; DIALYSIS; DRUG EFFECT; DYSGEUSIA; FETOPLACENTAL UNIT; FETOTOXICITY; GLUCOSURIA; HUMAN; HYPERKALEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTRAUTERINE GROWTH RETARDATION; KIDNEY FAILURE; LIMB MALFORMATION; LIVER TOXICITY; LUNG HYPOPLASIA; NEUTROPENIA; NEWBORN DEATH; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOHYDRAMNIOS; PATENT DUCTUS ARTERIOSUS; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RASH; RESPIRATORY DISTRESS SYNDROME; SIDE EFFECT; SKULL MALFORMATION;

EID: 0036955660     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/jmf.12.6.402.407     Document Type: Conference Paper

References (28)

1. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-12
2. Pickup JC, Williams G, eds. Textbook of Diabetes. Oxford, UK: Blackwell Scientific Publications, 1998:52.1-54.19
3. Osicka TM, Houlihan CA, Chan JG et al. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000;49:1579-84
4. Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perpective. Am J Kidney Dis 2002;39:899-919
5. Rosenberg C, Peters A. Patient education. In Davidson MB, ed. Diabetes Mellitus: Diagnosis and Treatment. Philadelphia: WB Saunders, 1998:355
6. Daniels BS, Goetz FC. Diabetes and the kidney. In Davidson JK, ed. Clinical Diabetes Mellitus: A Problem Oriented Approach. New York: Thieme, 2000:529-37
7. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67
8. Münzel T, Keaney JF. Current perspective: are ACE inhibitors a 'Magic Bullet' against oxidative stress? Circulation 2001;104:1571-4
9. Jackson EK. Drugs affecting renal and cardiovascular function. In Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw Hill, 2001:809-41
10. Björck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992;304:339-43
11. Parving H-H, Rossing P, Hommel E, et al. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995;26:99-107
12. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of antiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62
13. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus - a 7-year follow-up study. Arch Intern Med 1996; 156:286-9
14. Marre M, Chatellier G, Leblanc H. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988;297:1092-5
15. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 1991;303:81-7
16. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1998; 128: 982-8
17. Chaturvedi N, Stevenson J, Fuller JH, et al. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92
18. Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995. J Am Med Assoc 1997;277:1193-4
19. Easterling TR, Carr DB, Davis C, et al. Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol 2000;96:956-61
20. Miodovnik M, Rosenn BM, Khoury JC, et al. Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Gynecol 1996;174:1180-91
21. Burrows RF, Burrows EA. Occasional review: assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust NZ J Obstet Gynaecol 1998;38:306-11
22. Hod M, van Dijk DJ, Karp M, et al. Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Nephrol Dial Transplant 1995;10:2328-33
23. Rossing K, Jacobsen P, Hommel E, et al. Pregnancy and progression of diabetic nephropathy. Diabetologia 2002;45:36-41
24. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45
25. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type II diabetes. N Engl J Med 2001;345:851-60
26. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
27. Parving H-H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
28. Saji H, Yamanaka M, Hagiwara A, et al. Losartan and fetal toxic effects. Lancet 2001;357:363